Posts

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

on
AstraZeneca has received a key FDA nod for its new hypertension drug Baxfendy (baxdrostat), marking the first approval of an aldosterone synthase inhibitor for high blood pressure in the United States. This decision boosts AstraZeneca's pipeline in cardiovascular disease and supports its 2030 revenue target of $80 billion. The approval is based on Phase 3 BaxHTN trial data showing statistically significant reductions in systolic blood pressure when used in combination with other antihypertensives in patients with uncontrolled or treatment‑resistant hypertension. Concurrently, the FDA has extended an existing approval for AstraZeneca's asthma biologic Fasenra (benralizumab). The agency has cleared an expanded label or new use for Fasenra, reinforcing its role in eosinophilic diseases and broadening its eligible patient population. This dual FDA activity provides a "sweetener" for the company, pairing a novel hypertension product with an incremental gain for an establ...

Regeneron Signs $2.3 Billion Pact with Parabilis for Novel ADC-Like Antibody–Helicon Conjugates

on

Reframing What’s Possible in Pharma Commercialization (2026 Outlook)

on

Candel Therapeutics reports strong long‑term prostate cancer data ahead of FDA filing

on

CDER chief Høeg, skeptic of vaccines and antidepressants, is fired in high-level FDA shakeup

on

Valar Labs scores FDA breakthrough tag for AI‑based bladder cancer risk test

on

BMS-Hengrui $15B deal, Takeda 4.5K layoffs, and Daiichi's oncology ambition

on

Drugmakers must disclose U.S. production plans to qualify for tariff exemptions

on

Aardvark to unblind Phase 3 ARD-101 data early after FDA clinical hold

on

Biogen advances anti-tau Alzheimer’s drug diranersen despite mixed Phase 2 results

on

Mochida Pharmaceutical: Notice Concerning Changes in Directors

on

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Use AI and Real‑World Data to Improve Clinical Trial Success

on

Datar Cancer Genetics Announces US FDA Clearance for CellDx-Tissue

on